NPFFR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4508281	0.57	14/20
SCHEMBL1981602	0.53	11/20
SCHEMBL3167579	0.60	10/20
SCHEMBL4631287	0.57	10/20
SCHEMBL4502727	0.56	10/20
SCHEMBL3178014	0.67	8/20
SCHEMBL2996293	0.66	7/20
SCHEMBL4630062	0.58	7/20
SCHEMBL4517495	0.57	7/20
SCHEMBL2877082	0.56	7/20
SCHEMBL3958497	0.55	7/20
SCHEMBL2863163	0.54	7/20
SCHEMBL2864930	0.52	7/20
SCHEMBL2348786	0.64	6/20
SCHEMBL3171094	0.60	6/20
SCHEMBL2281940	0.59	6/20
SCHEMBL4511211	0.59	6/20
SCHEMBL3373869	0.58	6/20
SCHEMBL1997960	0.58	6/20
SCHEMBL1770778	0.57	6/20

Clinical trials — most relevant to NPFFR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
NP2 Enkephalin For Treatment of Intractable Cancer Pain	PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.	PHASE2	COMPLETED
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	PHASE1	COMPLETED
Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction	PHASE1	WITHDRAWN
[C-11]NPA PET-amphetamine in Cocaine Use Disorders	EARLY_PHASE1	RECRUITING
Imaging CRF X NOP Interactions in CUD	EARLY_PHASE1	RECRUITING
Acylated Ghrelin Response to Acute Exercise in Obesity	nan	COMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression	nan	COMPLETED
Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues	nan	UNKNOWN
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI	nan	UNKNOWN
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Acute Intermittent Hypoxia in Traumatic Brain Injury	nan	COMPLETED
Transcriptome Sequencing Analysis of Whole Blood From Patients With Trigeminal Neuralgia	nan	UNKNOWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
Multicenter Perioperative Opioid Pharmacogenetic Study	nan	COMPLETED
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response	nan	NOT_YET_RECRUITING
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Pharmacodynamics of CNP During Growth Hormone Treatment	nan	COMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NPFFR1 binder may also engage these)

Protein	Name	Similarity
Q9EP86	—	0.988	Q9EP86 →
O97661	—	0.987	O97661 →
Q0GBZ5	—	0.981	Q0GBZ5 →
HCRTR1	Orexin/Hypocretin receptor type 1	0.980	landscape →
P30935	—	0.978	P30935 →
P56718	—	0.978	P56718 →
P58307	—	0.978	P58307 →
P30936	—	0.977	P30936 →
RXFP3	Relaxin-3 receptor 1	0.971	landscape →
P49660	—	0.969	P49660 →
Q8BGE9	—	0.969	Q8BGE9 →
SSTR3	Somatostatin receptor type 3	0.967	landscape →
P30937	—	0.967	P30937 →
O62809	—	0.964	O62809 →
SSTR4	Somatostatin receptor type 4	0.962	landscape →
Q8HYC3	—	0.961	Q8HYC3 →
O08726	—	0.960	O08726 →
Q6TLI7	—	0.960	Q6TLI7 →
P49220	—	0.960	P49220 →
Q60613	—	0.959	Q60613 →
P11617	—	0.959	P11617 →
Q8VIH9	—	0.958	Q8VIH9 →
HTR6	5-hydroxytryptamine receptor 6	0.958	landscape →
GALR2	Galanin receptor type 2	0.957	landscape →
P49681	—	0.957	P49681 →
Q9TUP7	—	0.957	Q9TUP7 →
GALR3	Galanin receptor type 3	0.956	landscape →
O88854	—	0.956	O88854 →
Q56UD9	—	0.956	Q56UD9 →
NPBWR1	Neuropeptides B/W receptor type 1	0.955	landscape →